Thursday, May 28, 2020 1:14:44 PM
..........Holder.................Shares........Date Reported....% Out
Vanguard Group.........4,549,361.......Mar 30, 2020....1.50%
Blackrock....................2,007,529.......Mar 30, 2020....0.66%
Renaissance Tech......1,186,437.......Mar 30, 2020....0.39%
Sabby Management......621,840.......Mar 30, 2020....0.20%
Geode Capital...............603,389.......Mar 30, 2020....0.20%
Virtu Financial...............407,794.......Dec 30, 2019....0.13%
Northern Trust...............317,043.......Mar 30, 2020....0.10%
Bank Julius Baer...........241,368.......Mar 30, 2020....0.08%
PNC Financial...............198,480.......Mar 30, 2020....0.07%
UBS Group AG..............130,822.......Mar 30, 2020....0.04%
Top Mutual Fund Holders
..........Holder.................Shares........Date Reported....% Out
Vanguard Total Stock Market Index Fund 3,033,390 Dec 30, 2019 1.00% 660,369
Vanguard Extended Market Index Fund 1,395,872 Dec 30, 2019 0.46% 303,881
Fidelity Extended Market Index Fund 386,446 Jan 30, 2020 0.13% 96,959
Fidelity Total Market Index Fund 117,751 Jan 30, 2020 0.04% 29,543
Vanguard Institutional Index-Inst Total Stock Market Ind 97,444 Dec 30, 2019 0.03% 21,213
Schwab Capital Trust-Total Stock Market Index Fund 80,219 Oct 30, 2019 0.03% 20,014
Fidelity Series Total Market Index Fund 76,709 Jan 30, 2020 0.03% 19,246
Vanguard Balanced Index Fund 68,434 Dec 30, 2019 0.02% 14,898
iShares Core S&P Total U.S. Stock Market ETF 27,578 Jan 30, 2020 0.01% 6,919
Recent ATNM News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/06/2024 12:30:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 10:12:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 10:05:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/05/2024 10:00:36 PM
- Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors • PR Newswire (US) • 11/04/2024 12:30:00 PM
- Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology • PR Newswire (US) • 09/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 09:15:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:30:34 AM
- Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. • PR Newswire (US) • 08/05/2024 11:00:00 AM
- Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications • PR Newswire (US) • 08/01/2024 12:00:00 PM
- Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University • PR Newswire (US) • 07/25/2024 12:45:00 PM
- Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US • PR Newswire (US) • 07/25/2024 11:30:00 AM
- Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress • PR Newswire (US) • 06/17/2024 12:00:00 PM
- Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial • PR Newswire (US) • 06/14/2024 12:30:00 PM
- Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/11/2024 12:30:00 PM
- Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/10/2024 12:30:00 PM
- Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity • PR Newswire (US) • 05/15/2024 12:30:00 PM
- Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phas • PR Newswire (US) • 05/14/2024 10:38:00 PM
- Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 05/13/2024 12:30:00 PM
- Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting • PR Newswire (US) • 04/18/2024 12:00:00 PM
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy • PR Newswire (US) • 03/26/2024 11:18:00 AM
- Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand • PR Newswire (US) • 03/11/2024 11:30:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM